LifeVantage Corporation
NASDAQ•LFVN
CEO: Mr. Steven R. Fife CPA
Sector: Consumer Defensive
Industry: Packaged Foods
Listing Date: 1994-04-07
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement designed to strengthen immune health; LifeVantage Rise AM & Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3, vitamin K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; PhysIQ Fat Burn to support weight management; PhysIQ Prebiotic is a dietary supplement designed to support the good bacteria in the gut and a healthy microbiome; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, hand creams, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name. It sells its products through its website and network of independent consultants in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company is headquartered in Lehi, Utah.
Contact Information
3300 North Triumph Boulevard, Suite 700, Lehi, UT, 84043, United States
801-432-9000
Market Cap
$67.55M
P/E (TTM)
8.5
10.6
Dividend Yield
3.4%
52W High
$17.64
52W Low
$3.90
52W Range
Rank26Top 13.0%
5.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2026 Data
Revenue
$48.93M+0.00%
4-Quarter Trend
EPS
$0.02+0.00%
4-Quarter Trend
FCF
$1.71M+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Six-Month Revenue Decline Six-month revenue totaled $96.5M, down 16.4% from $115.0M prior period, driven by sharp product sales contraction.
Sharp Profitability Contraction Quarterly net income $276K versus $2.55M last year, reflecting significant margin compression across operations.
Consultant Network Shrinkage Total active consultants fell 5,000 to 47,000, representing 9.6% decline from prior year active base as of December 31.
LoveBiome Acquisition Closed Completed LoveBiome asset acquisition October 1, 2025, paying $3.74M cash consideration for strategic growth assets.
Risk Factors
Gross Margin Erosion Gross margin dropped 6.5 points to 74.0% due to $2.4M inventory obsolescence costs impacting profitability metrics.
Customer Base Contraction Active customer count fell 26,000 (32.5%) in Americas region, signaling significant customer retention challenges.
Liquidity Reduction Cash and equivalents decreased $10.0M sequentially to $10.2M; six-month operating cash flow fell $8.1M.
Product Sales Concentration Dependence on MindBody GLP-1 System sales, which decreased $16.2M quarterly, creates substantial revenue concentration risk.
Outlook
International Product Expansion Plan to refine and expand LoveBiome and MindBody GLP-1 product lines internationally through remainder of fiscal 2026.
Sufficient Liquidity Expected Management believes current cash balances and operating cash flow will suffice for next 12 months obligations.
New Market Entry Company commenced operations in Iceland in September 2025, supporting global sales and marketing initiatives.
Credit Facility Status No balance outstanding on the $5.0M 2024 Credit Facility as of December 31, 2025, providing financial flexibility.
Peer Comparison
Revenue (TTM)
$1.51B
$515.77M
$376.91M
Gross Margin (Latest Quarter)
74.0%
60.2%
47.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ACU | $164.30M | 16.1 | 12.1% | 16793.8% |
| LFVN | $67.55M | 8.5 | 25.0% | 17.5% |
| CHGG | $64.47M | -0.6 | -67.9% | 30.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-5.7%
Growth Under Pressure
4Q Net Income CAGR
-57.0%
Declining Profitability
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 30, 2026
EPS:$0.16
|Revenue:$47.77M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data